"Inactivation, Metabolic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion.
| Descriptor ID |
D008658
|
| MeSH Number(s) |
G03.171.450 G03.787.225.450 G07.690.725.225.450
|
| Concept/Terms |
Metabolic Detoxication, Drug- Metabolic Detoxication, Drug
- Detoxication, Drug Metabolic
- Drug Metabolic Detoxication
- Drug Detoxication, Metabolic
- Detoxication, Metabolic Drug
- Metabolic Drug Detoxication
- Metabolic Detoxification, Drug
- Detoxification, Drug Metabolic
- Drug Metabolic Detoxification
- Detoxification, Drug, Metabolic
- Detoxication, Drug, Metabolic
|
Below are MeSH descriptors whose meaning is more general than "Inactivation, Metabolic".
Below are MeSH descriptors whose meaning is more specific than "Inactivation, Metabolic".
This graph shows the total number of publications written about "Inactivation, Metabolic" by people in this website by year, and whether "Inactivation, Metabolic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Inactivation, Metabolic" by people in Profiles.
-
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer. Nat Commun. 2019 12 06; 10(1):5604.
-
Significant difference in active metabolite levels of ginseng in humans consuming Asian or Western diet: The link with enteric microbiota. Biomed Chromatogr. 2017 Apr; 31(4).
-
The limits of genome-wide methods for pharmacogenomic testing. Pharmacogenet Genomics. 2012 Apr; 22(4):261-72.
-
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011 Jun; 12(5):487-97.
-
Diabetes and hypertriglyceridemia modify the mode of acetaminophen-induced hepatotoxicity and nephrotoxicity in rats and mice. J Toxicol Sci. 2009 Feb; 34(1):1-11.
-
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006 Dec; 7(8):1211-21.
-
Pharmacogenetics in cancer treatment. Annu Rev Med. 2003; 54:437-52.
-
Enhanced nephrotoxicity of acetaminophen in fructose-induced hypertriglyceridemic rats: contribution of oxidation and deacetylation of acetaminophen to an enhancement of nephrotoxicity. Exp Toxicol Pathol. 1997 Dec; 49(5):313-9.